靶向心肌收缩力的治疗:从病理生理到临床转化
该立场文件综述了急性心力衰竭(HF)和心源性休克中正性肌力药物的治疗困境:儿茶酚胺类和磷酸二酯酶抑制剂虽改善收缩功能但增加死亡率,而左西孟旦和omecamtiv mecarbil靶向肌节。文章从兴奋-收缩耦联、线粒体生物能量学和氧化还原调控角度探讨不同正性肌力药物的机制,旨在识别能安全改善收缩和舒张功能并长期改善心肌结构的治疗新靶点。
要点
- 传统正性肌力药(儿茶酚胺类、PDE抑制剂)改善收缩功能但增加死亡率。
- 左西孟旦和omecamtiv mecarbil靶向肌节, putative不升高细胞内钙。
- 线粒体ATP和活性氧产生与兴奋-收缩耦联紧密关联,是潜在治疗靶点。
核心结论
- 急性HF和心源性休克病死率高,传统正性肌力药增加死亡率,需寻找能安全改善收缩和舒张功能并长期改善心肌结构的新靶点。
研究设计与样本
- 立场文件(position paper),回顾HF收缩功能不全的病理生理基础及不同正性肌力药物改善心脏功能的机制。
主要发现
- 儿茶酚胺或磷酸二酯酶抑制剂等正性肌力药与死亡率增加相关。
- 左西孟旦和omecamtiv mecarbil靶向肌节,putatively不升高细胞内Ca2+。
- 左西孟旦的小型试验荟萃分析提示结局优于多巴胺,但较大对比试验未能证实。
- omecamtiv mecarbil的II期试验提示在急性和慢性HF中血流动力学特征良好,慢性HF的III期 morbidity/mortality试验已启动。
- 线粒体ATP和活性氧产生与兴奋-收缩耦联过程紧密相关,正性肌力药影响线粒体生物能量学和氧化还原调控。
临床怎么用
- 临床需权衡正性肌力药改善血流动力学与增加死亡风险,关注靶向肌节且不升高细胞内钙的新药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute heart failure (HF) and in particular, cardiogenic shock are associated with high morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents, such as catecholamines or phosphodiesterase-inhibitors, is associated with increased mortality. Newer drugs, such as levosimendan or omecamtiv mecarbil, target sarcomeres to improve systolic function putatively without elevating intracellular Ca2+. Although meta-analyses of smaller trials suggested that levosimendan is associated with a better outcome than dobutamine, larger comparative trials failed to confirm this observation. For omecamtiv mecarbil, Phase II clinical trials suggest a favourable haemodynamic profile in patients with acute and chronic HF, and a Phase III morbidity/mortality trial in patients with chronic HF has recently begun. Here, we review the pathophysiological basis of systolic dysfunction in patients with HF and the mechanisms through which different inotropic agents improve cardiac function. Since adenosine triphosphate and reactive oxygen species production in mitochondria are intimately linked to the processes of excitation-contraction coupling, we also discuss the impact of inotropic agents on mitochondrial bioenergetics and redox regulation. Therefore, this position paper should help identify novel targets for treatments that could not only safely improve systolic and diastolic function acutely, but potentially also myocardial structure and function over a longer-term.
引用
- Maack C, Eschenhagen T, Hamdani N, et al. Treatments targeting inotropy. Eur Heart J. 2019. PMID: 30295807. doi:10.1093/eurheartj/ehy600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。